Nasdaq stocks posting largest volume increases
AP - Tue Dec 23, 5:07PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
INTG: 17.90 (+0.01), NICK: 14.80 (+0.20), ADXS: 7.57 (+0.50), WBKC: 23.47 (+0.03), SOCB: 7.20 (+0.03), CBIN: 27.50 (-0.28), UPI: 2.30 (unch), CTIB: 3.74 (-0.06), SONA: 11.29 (unch)
Nasdaq stocks posting largest percentage increases
AP - Tue Dec 23, 5:07PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
CYTK: 5.87 (+0.35), RDUS: 37.17 (+0.11), NICK: 14.80 (+0.20), VSAR: 22.25 (-0.11), ADXS: 7.57 (+0.50), VNDA: 14.69 (+1.11), CZR: 15.44 (+0.20)
Advaxis continues cancer immunotherapy-stoked up move
Seeking Alpha - at Seeking Alpha - Mon Dec 22, 11:58AM CST
ADXS: 7.57 (+0.50), AZN: 70.44 (+0.26)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Dec 22, 11:50AM CST
ADXS: 7.57 (+0.50), SANW: 3.98 (-0.02), ASPS: 33.81 (+4.37), OCN: 14.88 (-0.14), ZAZA: 3.20 (+0.70), SGOC: 0.61 (-0.02), AAMC: 335.99 (-4.00), VOC: 5.60 (-0.09), TECU: 3.59 (-0.14), RDUS: 37.17 (+0.11), IRMD: 12.64 (+0.14), SKYS: 11.05 (-0.95), VSCI: 0.76 (-0.07), CALA: 22.33 (+1.16), REXX: 5.17 (-0.17), CFRX: 3.99 (+0.10), TRXC: 2.79 (+0.03), CHNR: 1.92 (-0.15), CNET: 1.28 (-0.11), DRYS: 1.20 (-0.04)
Pharma Deals Watch: Coverage Initiated on AstraZeneca, Advaxis, Radius Health, Cubist and AbbVie
PR Newswire - Mon Dec 22, 8:00AM CST
Moments ago, Analysts Review released new research updates concerning several important developing situations including AstraZeneca (NYSE: AZN), Advaxis (NASDAQ: ADXS), Radius Health (NASDAQ: RDUS), Cubist (NASDAQ: CBST), and AbbVie (NYSE: ABBV). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
RDUS: 37.17 (+0.11), ADXS: 7.57 (+0.50), CBST: 100.29 (-0.09), AZN: 70.44 (+0.26), ABBV: 66.21 (+1.86)
Advaxis Completes $17 Million Financing
GlobeNewswire - Fri Dec 19, 2:34PM CST
Advaxis, Inc. (Nasdaq:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, announced today that it has executed definitive securities purchase agreements with two institutional investors for gross proceeds of approximately $16.7 million in a registered direct offering of approximately 3.9 million shares at a price of $4.25 per share.
ADXS: 7.57 (+0.50)
Advaxis Announces FDA Acceptance of Its Investigational New Drug Application to Commence Clinical Trials of ADXS-HPV in Combination With MedImmune's MEDI4736 for the Treatment of HPV-Associated Cancers
GlobeNewswire - Mon Dec 15, 6:39AM CST
Advaxis, Inc. (Nasdaq:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application to conduct a Phase 1/2 clinical study of ADXS-HPV (ADXS11-001) alone or in combination with MedImmune's investigational anti-PD-L1 immune checkpoint inhibitor, MEDI4736, for the treatment of advanced, recurrent or refractory human papillomavirus (HPV)-associated cervical cancer and HPV-associated head and neck cancer. The trial is expected to begin patient enrollment in early 2015.
ADXS: 7.57 (+0.50)
Advaxis's Cancer Immunotherapies Featured on FOX News
GlobeNewswire - Fri Dec 12, 6:30AM CST
Advaxis, Inc. (Nasdaq:ADXS), a biotechnology company developing cancer immunotherapies, announced that its Lm-LLO immunotherapy technology is featured on FOX News Channel in a broadcast segment and article, entitled, "Teaching the immune system to fight back against cancer."
ADXS: 7.57 (+0.50)
Advaxis's Listeria-based Lm-LLO Immunotherapy Featured in Nature Biotechnology
GlobeNewswire - Thu Dec 11, 6:30AM CST
Advaxis, Inc. (Nasdaq:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, announced today that its Lm-LLO immunotherapy technology is featured in an article in the December 2014 issue of Nature Biotechnology. Entitled "Listeria vaccines join the checkpoint frenzy," the article explores the potential of the Listeria bacterium as a vector to enhance an anti-tumor response given its ability to induce powerful innate and adaptive immune responses.
ADXS: 7.57 (+0.50)
Advaxis Announces FDA Acceptance of Its Investigational New Drug Application to Commence Clinical Trials of ADXS-PSA in Combination With Merck's KEYTRUDA(R) (pembrolizumab) for Prostate Cancer
GlobeNewswire - Mon Dec 08, 6:30AM CST
Advaxis, Inc. (Nasdaq:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application to conduct a Phase 1/2 clinical study to evaluate the combination of ADXS-PSA (ADXS31-142) with KEYTRUDA (pembrolizumab), marketed by Merck & Co., Inc., in patients with previously treated, metastatic castration-resistant prostate cancer (mCRPC). The clinical trial, which will be the first-in-human study of Advaxis's lead Lm-LLO immunotherapy product candidate in prostate cancer, is expected to begin patient enrollment in the first quarter of 2015.
ADXS: 7.57 (+0.50), MRK: 57.46 (+0.25)
InMed Pharma's Hiring of Tiberend Highlights Biotech Focus
ACCESSWIRE - Wed Dec 03, 9:32AM CST
WHITEFISH, MT / ACCESSWIRE / December 3, 2014 / Cannabis based medicine is being widely adopted as the next exciting special interest sector of the biotech community. With GW Pharmaceuticals plc (NASDAQ: GWPH) and others conducting clinical trials targeting important indications like cancer pain and arthritis, the data collected so far has suggested that cannabinoids could have far-reaching beneficial effects on the human body.
ADXS: 7.57 (+0.50), GWPH: 68.08 (+1.82), GALE: 1.49 (-0.02)
Advaxis to Present at the LD Micro Conference
GlobeNewswire - Tue Nov 25, 6:30AM CST
Advaxis, Inc. (Nasdaq:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, announced today that it will present at the LD Micro Conference being held December 2-4, 2014 at the Luxe Hotel in Los Angeles, California.
ADXS: 7.57 (+0.50)
MarketExclusive.com - Nobel Financial Reiterates Buy Rating of Advaxis, Inc. Based on a Review of Recent Data Presentations and IND Submissions
ACCESSWIRE - Mon Nov 24, 11:45AM CST
NEW YORK, NY / ACCESSWIRE / November 24, 2014 / Market Exclusive announces that Nobel Financial has reiterated a Buy rating of Advaxis, Inc. (Nasdaq: ADXS) with a 12-month target price of $12. The Buy rating is based on a review of recent data presentations and IND submissions.
ADXS: 7.57 (+0.50)
Advaxis, Inc. - "From Two Checkpoint Inhibitor Development Agreements to Two IND Filings in Four Months - A Special Thanksâ?¦"
ACCESSWIRE - Mon Nov 24, 7:23AM CST
New York, NY / ACCESSWIRE / November 24, 2014 / Advaxis, Inc. (NASDAQ: ADXS) today published a new blog post on The Chairman's Blog, written by the Company's CEO, Daniel J. O'Connor. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
ADXS: 7.57 (+0.50)
Advaxis to Receive $1.7M Through New Jersey Technology Business Tax (NOL) Program
GlobeNewswire - Thu Nov 20, 6:36AM CST
Advaxis, Inc. (Nasdaq:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, announced it has received preliminary approval for a $1.9M tax credit from the New Jersey Technology Business Tax Certificate Transfer (NOL) Program for the year 2014. The Company anticipates that it will be able to transfer this credit and receive approximately $1.7 million in cash in mid-December.
ADXS: 7.57 (+0.50)
Global Cervical Cancer Therapeutic Pipeline Review, H2 2014 - 35 Companies & 71 Drug Profiles
M2 - Wed Nov 19, 4:19AM CST
Research and Markets (http://www.researchandmarkets.com/research/4p52hn/cervical_cancer) has announced the addition of the "Cervical Cancer - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cervical Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cervical Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - F. Hoffmann-La Roche Ltd. - Sanofi - GlaxoSmithKline plc - Nektar Therapeutics - Inovio Pharmaceuticals, Inc. - Daiichi Sankyo Company, Limited - Amorfix Life Sciences Ltd. - MediGene AG - Nanotherapeutics, Inc. - Arbor Vita Corporation - Novartis AG - Chong Kun Dang Pharmaceutical Corp. - Taiho Pharmaceutical Co., Ltd. - Zeria Pharmaceutical Co Ltd - Genmab A/S - Advaxis, Inc. - 3SBio Inc. - Transgene SA - Antigen Express, Inc. - Shantha Biotechnics Limited - Bionor Pharma ASA - Azaya Therapeutics Incorporated - Merrimack Pharmaceuticals, Inc. - Genexine, Inc. - Genticel - Sirnaomics, Inc. - EyeGene, Inc. - Vaccibody AS - Wellstat Biologics Corporation - ISA Pharmaceuticals B.V. For more information visit http://www.researchandmarkets.com/research/4p...cal_cancer
MACK: 10.91 (+0.36), INO: 9.11 (-0.09), ADXS: 7.57 (+0.50), GSK: 42.85 (+0.11), NKTR: 15.02 (+0.23), NVS: 93.91 (+0.66)
Advaxis Is Undervalued With Multiple Partnerships And Near-Term Commercialization Potential In 2015
Tony Schwartz, PhD - at Seeking Alpha - Thu Nov 13, 1:51PM CST
ADXS: 7.57 (+0.50)
Advaxis submits IND for HPV-associated cancers
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 10:13AM CST
ADXS: 7.57 (+0.50), AZN: 70.44 (+0.26)
Advaxis Submits Investigational New Drug Application for Phase 1/2 Study of ADXS-HPV and MedImmune's MEDI4736 for the Treatment of HPV-Associated Cervical and Head & Neck Cancer
GlobeNewswire - Wed Nov 12, 6:30AM CST
Advaxis, Inc. (Nasdaq:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, today announced that the Company has submitted an Investigational New Drug application (IND) to the United States Food and Drug Administration (FDA) to conduct a Phase 1/2 study of ADXS-HPV (ADXS11-001) alone or in combination with MedImmune's investigational anti-PD-L1 immune checkpoint inhibitor, MEDI4736, for the treatment of advanced, recurrent or refractory human papillomavirus (HPV)-associated cervical cancer and HPV-associated head and neck cancer.
ADXS: 7.57 (+0.50)